Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma News
-
By Kevin E. Noonan — In a recent article in the journal Science, Sherry Knowles, the Chief Patent Counsel at GlaxoSmithKline, raises several interesting questions regarding the concept of "takings" of property in the patent context. In a "Policy Forum" article entitled "Fixing the Legal Framework for Pharmaceutical Research," Ms. Knowles (at right) tackles…
-
By Donald Zuhn — On Tuesday, Representative Diana DeGette (D-CO) introduced legislation (H.R. 4808) that would amend the Public Health Service Act to provide for human embryonic stem cell research. H.R. 4808 would codify President Obama's Executive Order 13505, which permitted federal funding of research conducted with human embryonic stem cell lines. It was…
-
By Donald Zuhn — Last month, Bill and Melinda Gates kicked off the new decade by announcing that their Foundation will be pledging $10 billion over the next ten years to help research, develop, and deliver vaccines to the world's poorest countries. The announcement came at the World Economic Forum's annual meeting in January.…
-
By Kevin E. Noonan — Myriad Genetics, one of the preeminent gene-based diagnostics companies, has been targeted by the American Civil Liberties Union, Dan Ravicher’s PUBPAT Organization, a raft of medical researchers and their associations, and individual patients in a lawsuit filed in the Southern District of New York; the avowed aim of the…
-
Implications for Patent Protection for Avonex® Anti-Multiple Sclerosis Drug By Kevin E. Noonan — There is a tendency to blame the process when an undesired outcome occurs. That is happening in the wake of regulatory filings with the Securities and Exchange Commission regarding U.S. Patent 7,588,755 (the '755 patent), issued on September 15, 2009,…
-
By Donald Zuhn — Last month, ChemBridge Corp. announced that it would make ten of its most popular chemical screening libraries available to researchers via the Collaborative Drug Discovery (CDD) Public Access database. The CDD Public Access database, a collection of public data from leading vendors, researchers, scientific literature, and patent resources, is hosted by…
-
By Kevin E. Noonan — The fastest-growing part of the biotech/pharma industry is anticancer drugs, according to an article in The New York Times today ("For Profit, Industry Seeks Cancer Drugs"). Written by Andrew Pollack, one of the paper's senior business and technology writers, the article highlights the interplay between scientific interest and business…
-
By Kevin E. Noonan — One of the benefits of the exponential increase in genetic information consequent to the determination of the genomic DNA sequence of numerous species (the various "genome projects" that include the Human Genome Project) is that it permits sequence comparisons between related species. One result of this new knowledge has…
-
By Kevin E. Noonan — The genetic age, characterized by numerous genome projects (not the least of which is the Human Genome Project) has focused the public's attention on the influence of our genes on our characteristics. This has led to questions about whether there is a "gene" for risk-taking, or homosexuality, or aggressiveness. …
-
By Kevin E. Noonan — A research paper in the June 2009 edition of Nature Biotechnology (Eguchi et al., 2009, "Efficient siRNA delivery into primary cells by a peptide transduction domain–dsRNA binding domain fusion protein," Nature Biotechnology 27: 567-71) describes a new system for introducing short interfering RNAs (siRNAs) into mammalian cells that may…
Patent Docs 